Vascular perfusion and hypoxic areas in RIF-1 tumours after photodynamic therapy.

The influence of photodynamic therapy (PDT) on vascular perfusion and the development of hypoxia was investigated in the murine RIF-1 tumour. Image analysis was used to quantify changes in perfusion and hypoxia at 5 min after interstitial Photofrin-mediated PDT. The fluorescent stain Hoechst 33342 was used as an in vivo marker of functional vascular perfusion and the antibody anti-collagen type IV as a marker of the tumour vasculature. The percentage of total tumour vasculature that was perfused decreased to less than 30% of control values after PDT. For the lower light doses this decrease was more pronounced in the centre of the tumour. The observed reduction in vascular perfusion showed a good linear correlation (r = 0.98) with previously published tumour perfusion data obtained with the 86Rb extraction technique. The image analysis technique provides extra information concerning the localisation of (non)-perfused vessels. To detect hypoxic tumour areas in vivo, an immunohistochemical method was used employing NITP [7-(4'-(2-nitroimidazol-1-yl)-butyl)-theophylline]. A large increase in hypoxic areas was found for PDT-treated tumours. More than half the total tumour area was hypoxic after PDT, compared with < 4% for control tumours. Our studies illustrate the potential of image analysis systems for monitoring the functional consequences of PDT-mediated vascular damage early after treatment. This provides direct confirmation that the perfusion changes lead to tissue hypoxia, which has implications for the combined treatment of PDT with bioreductive drugs.

[1]  J. Gray,et al.  A new mouse tumor model system (RIF-1) for comparison of end-point studies. , 1980, Journal of the National Cancer Institute.

[2]  G. Wilson,et al.  Flow cytometric evaluation of hypoxic cells in solid experimental tumours using fluorescence immunodetection. , 1991, British Journal of Cancer.

[3]  D. Chaplin,et al.  The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain. , 1987, International journal of radiation oncology, biology, physics.

[4]  S. Fox,et al.  TUMOUR ANGIOGENESIS , 1996, The Journal of pathology.

[5]  M. Trotter,et al.  The use of fluorescent probes to identify regions of transient perfusion in murine tumors. , 1989, International journal of radiation oncology, biology, physics.

[6]  A. Rauth,et al.  Oxygen tension, cellular respiration, and redox state as variables influencing the cytotoxicity of the radiosensitizer misonidazole. , 1982, Radiation research.

[7]  C. Koch Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. , 1993, Cancer research.

[8]  P. Okunieff,et al.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. , 1989, Cancer research.

[9]  M. Trotter,et al.  Effect of vascular marker Hoechst 33342 on tumour perfusion and cardiovascular function in the mouse. , 1990, British Journal of Cancer.

[10]  E. C. Beuvery,et al.  Analysis of glycoforms present in two mouse IgG2a monoclonal antibody preparations. , 1992, Journal of immunological methods.

[11]  M R Arnfield,et al.  Oxygen dependency of tumor cell killing in vitro by light-activated Photofrin II. , 1991, Radiation research.

[12]  H. Oppelaar,et al.  Enhancement of interstitial photodynamic therapy by mitomycin C and EO9 in a mouse tumour model , 1994, International journal of cancer.

[13]  A. Begg,et al.  Fluorescent markers of hypoxic cells: a comparison of two compounds on three cell lines. , 1985, The British journal of radiology.

[14]  P. Allen,et al.  Nuclear magnetic resonance spectroscopy and sensitizer-adduct measurements of photodynamic therapy-induced ischemia in solid tumors. , 1991, Journal of the National Cancer Institute.

[15]  T. Mang,et al.  Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy. , 1985, Cancer research.

[16]  L. H. Gray,et al.  The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy , 1955, British Journal of Cancer.

[17]  T. Oostendorp,et al.  Vascularity and perfusion of human gliomas xenografted in the athymic nude mouse. , 1995, British Journal of Cancer.

[18]  G. Adams,et al.  Increasing the effect of photodynamic therapy on the RIF-1 murine sarcoma, using the bioreductive drugs RSU1069 and RB6145. , 1992, British Journal of Cancer.

[19]  R. Moore,et al.  Measurement of PDT-induced hypoxia in Dunning prostate tumors by iodine-123-iodoazomycin arabinoside. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  W. Star,et al.  Destruction of rat mammary tumor and normal tissue microcirculation by hematoporphyrin derivative photoradiation observed in vivo in sandwich observation chambers. , 1986, Cancer research.

[21]  A. J. van der Kogel,et al.  Application of an image analysis system to the quantitation of tumor perfusion and vascularity in human glioma xenografts. , 1995, Microvascular research.

[22]  R. Mulcahy Effect of oxygen on misonidazole chemosensitization and cytotoxicity in vitro. , 1984, Cancer research.

[23]  H. Oppelaar,et al.  Changes in perfusion of mouse tumours after photodynamic therapy , 1994, International journal of cancer.

[24]  D. Chaplin,et al.  Intermittent blood flow in a murine tumor: radiobiological effects. , 1987, Cancer research.

[25]  H. Oppelaar,et al.  Photosensitizing efficacy of MTHPC‐PDT compared to Photofrin‐PDT in the RIF1 mouse tumour and normal skin , 2006, International journal of cancer.

[26]  T. Foster,et al.  Oxygen consumption and diffusion effects in photodynamic therapy. , 1991, Radiation research.

[27]  M R Arnfield,et al.  Treatment of Dunning R3327-AT rat prostate tumors with photodynamic therapy in combination with misonidazole. , 1986, Cancer research.

[28]  A. Rauth,et al.  Modification of the cytotoxic activity of mitomycin C by oxygen and ascorbic acid in Chinese hamster ovary cells and a repair-deficient mutant. , 1986, Cancer research.

[29]  B W Henderson,et al.  Relationship of tumor hypoxia and response to photodynamic treatment in an experimental mouse tumor. , 1987, Cancer research.

[30]  H. Oppelaar,et al.  Interaction of the bioreductive drug SR 4233 and photodynamic therapy using photofrin in a mouse tumor model. , 1993, International journal of radiation oncology, biology, physics.